2H51 Stock Chart & Stats
€1.18
-€0.07(-5.85%)
At close: 4:00 PM EDT
€1.18
-€0.07(-5.85%)
Day’s Range― - ―
52-Week Range€0.72 - €2.35
Previous CloseN/A
Volume3.00K
Average Volume (3M)13.61K
Market Cap
€235.48M
Enterprise Value€506.12M
Total Cash (Recent Filing)€100.05M
Total Debt (Recent Filing)€87.99M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding339,110,400
10 Day Avg. Volume16,579
30 Day Avg. Volume13,611
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.10Price Target Upside671.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.23
Revenue Forecast (FY)€4.38M
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline ProgressFDA clearance and RMAT designation reduce development uncertainty for OCU410, while OCU400 and OCU410ST have advanced into late-stage testing with defined data and filing timelines. Multiple programs create several potential paths to regulatory and commercial progress.
Strategic Licensing EconomicsThe MENA licensing agreement validates external interest in OCU400 and creates potential non-dilutive economics through upfront payments, milestones and royalties. It also expands regional commercialization reach while allowing Ocugen to manufacture supply.
Development Funding And ReadinessThe financing extends stated cash runway into 2028, supporting three late-stage programs through important clinical and regulatory milestones. Completed PPQ batches also indicate preparation for potential BLA submissions and commercial supply.
Bears Say
Negative Equity And Rising DebtNegative equity combined with sharply higher debt weakens financial flexibility and increases dependence on refinancing or equity-related solutions. This structure can constrain investment choices and amplify dilution risk if additional capital is required.
Persistent Cash BurnThe company remains substantially cash-consuming rather than self-funding, with operating and free cash flow deeply negative. Continued outflows require sustained access to financing, partnerships or other capital sources to advance the development pipeline.
Clinical Outcome UncertaintyUnclear interim treatment-effect data for OCU410ST create a meaningful execution risk because the program’s value depends on demonstrating efficacy in a small, developing dataset. Further follow-up may clarify outcomes but could delay or weaken regulatory and commercial prospects.
Ocugen News
2H51 FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was €0.72 and its highest was €2.35 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is €235.48M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Nov 10, 2026 which is in 23 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Aug 06, 2026. The company reported -€0.062 earnings per share for the quarter, missing the consensus estimate of -€0.047 by -€0.015.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.05.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 339,110,400 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -€0.062 in its last earnings report, missing expectations of -€0.047. Following the earnings report the stock price went up 0.709%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in DE:2H51
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.10 (671.33% Upside)
€9.10 (671.33% Upside)
Blogger Sentiment
Bullish
DE:2H51 Sentiment 75%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.55%
12-Months-Change
Fundamentals
Return on Equity
1688.22%
Trailing 12-Months
Asset Growth
131.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
2H51 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple significant clinical and regulatory advances — FDA clearance to start the Phase 3 GA trial with RMAT designation, strong Phase II efficacy signals for OCU410, completed enrollments and clear timelines for Phase III readouts for OCU400 and OCU410ST, manufacturing PPQs complete, a $130M financing and cash runway into 2028, and a MENA partnership — all material execution milestones. Offsetting these positives are rising operating expenses and a larger reported net loss per share, continued dependence on additional financing levers (which could be dilutive), and customary regulatory/timing and commercialization uncertainties. Overall, the operational and clinical progress and strengthened balance sheet outweigh the financial and execution risks discussed on the call.View all DE:2H51 earnings summaries2H51 Stock 12 Month Forecast
Average Price Target
€9.10
▲(671.33% Upside)